New daily pill hopes to shrink Hard-to-Treat cancers

NCT ID NCT06678659

Recruiting now Disease control Sponsor: Recursion Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental daily pill called REC-1245 in people with advanced solid tumors or lymphomas that have not responded to or are not eligible for standard therapies. The main goals are to find a safe dose and check if the drug can shrink tumors. About 170 adults will take part across multiple locations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED METASTATIC CANCERS RELAPSED/REFRACTORY LYMPHOMAS UNRESECTABLE

Contacts and locations

Show contact details

Locations

City of Hope
RECRUITING

Duarte, California, 91010, United States
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States

Contact Email: •••••@•••••
McGill University Health Centre (MUHC) - The Montreal
RECRUITING

Québec, H4A3J1, Canada
Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 1X6, Canada
SCRI Oncology Partners - PPDS
WITHDRAWN

Nashville, Tennessee, 37203, United States
START Mountain Region
RECRUITING

West Valley City, Utah, 84119, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.